Fig. 5

(A) Predictive performances of the MRI model across three molecular subtypes. (B) Performances of the three models concerning prediction of pathologic complete response to neoadjuvant therapy in all breast cancer patients. (C) Nomogram constructed based on the combined model. Each point that corresponds to each variable is on the uppermost point scale. The sum of all points is the total points. The point total projected at the bottom scale indicates the probability of pCR in the breast. The clinicopathologic model includes progesterone receptor and human epidermal growth factor receptor-2 statuses.The MRI model includes T2-c and T2-φ. The combined model includes progesterone receptor status, human epidermal growth factor receptor-2 status, T2-c, and T2-φ. AUC = area under the receiver operating characteristic curve, HER2 = human epidermal growth factor receptor-2, TNBC = triple-negative breast cancer